25. The aforesaid ratio lays down the guidelines for ascertaining whether the test of marketability is satisfied in a given case or otherwise. The litmus test is, whether the article is capable of being bought and sold, and the true meaning of being bought and sold to a consumer, means the commercial identity of the article as is known in the market for being bought and sold in the market, and the fact whether the product in question is generally not being bought or sold or has no demand in the market, would be irrelevant for determination of marketability. In the present case, the Digital Telephone Exchange (DLTEE), as a commodity, is known in the market as the supply of the said product has been tendered and necessary Purchase Orders were also placed on M/s. Alcatel Network Systems India Ltd. for supply of the said System. This indicates that the said Digital Switching System is being bought and sold and therefore, the test of marketability is satisfied in the present case. Since the twin test of movability and marketability, as laid down inMedley Pharmaceuticals Ltd. case, had been satisfied, we have no hesitation to observe that the product emerged after assembly of various parts at Panihati known as DLTEE, is an excisable goods and leviable to excise duty under Chapter Heading 85.17 of the CETA.
5. We have carefully considered the grounds of appeal and
submissions of appellant advanced by the learned AR for the
Page 3 of 5
E/1040/2010
Revenue. The short issue for determination is, whether the
valuation of physician sample be in accordance with Rule 8 or
Rule 4 of the Central Excise (Valuation) Rules, 2000. We find
that the Hon'ble Supreme Court in Medley Pharmaceuticals case
(supra) has laid down the principle as follows:
5. We have carefully considered the grounds of appeal and
submissions of appellant advanced by the learned AR for the
Revenue. The short issue for determination is, whether the
valuation of physician sample be in accordance with Rule 8 or
Rule 4 of the Central Excise (Valuation) Rules, 2000. We find
that the Hon'ble Supreme Court in Medley Pharmaceuticals case
(supra) has laid down the principle as follows:
5. We have carefully considered the grounds of appeal and
submissions of appellant advanced by the learned AR for the Revenue.
The short issue for determination is, whether the valuation of physician
sample be in accordance with Rule 8 or Rule 4 of the Central Excise
Valuation Rules, 2000. We find that the Hon'ble Supreme Court in
Medley Pharmaceuticals case (supra) has laid down the principle as
follows:
R-263/2007 which was Department - do -
upheld by the appeal allowed
Commissioner citing
Medley Pharmaceuticals
Ltd Vs C.Ex & Cus, Daman
2011 (263) Ε LT 641
(S.C) and Cadbury India
Ltd 2006-TIOL-88-SC-CX
which held Valuation
under Rule 4 to be
retrospective
R-263/2007 which was Department - do -
upheld by the appeal allowed
Commissioner citing
Medley Pharmaceuticals
Ltd Vs C.Ex & Cus, Daman
2011 (263) Ε LT 641
(S.C) and Cadbury India
Ltd 2006-TIOL-88-SC-CX
which held Valuation
under Rule 4 to be
retrospective
R-263/2007 which was Department - do -
upheld by the appeal allowed
Commissioner citing
Medley Pharmaceuticals
Ltd Vs C.Ex & Cus, Daman
2011 (263) Ε LT 641
(S.C) and Cadbury India
Ltd 2006-TIOL-88-SC-CX
which held Valuation
under Rule 4 to be
retrospective